Document is current
Any future updates will be listed below
-
Authors
Daines, Luke https://orcid.org/0000-0003-0564-4000
Canny, Anne https://orcid.org/0000-0003-1156-383X
Donaghy, Eddie https://orcid.org/0000-0002-7383-0107
Murray, Victoria
Campbell, Leo
Stonham, Carol
Milne, Heather
Price, David https://orcid.org/0000-0002-9728-9992
Buchner, Mark
Nelson, Lesley
Mair, Frances S. https://orcid.org/0000-0001-9780-1135
Sheikh, Aziz https://orcid.org/0000-0001-7022-3056
Bush, Andrew https://orcid.org/0000-0001-6756-9822
McKinstry, Brian https://orcid.org/0000-0001-9581-0468
Pinnock, Hilary https://orcid.org/0000-0002-5976-8386
-
Funding
Funding for this research was provided by:
Asthma and Lung UK,United Kingdom (AUK-PG-2018-404, AUK-PG-2018-404, AUK-PG-2018-404, AUK-PG-2018-404, AUK-PG-2018-404, AUK-PG-2018-404, AUK-PG-2018-404, AUK-PG-2018-404)
Asthma UK Centre for Applied Research
- License Information
-
More Information
Article History
Received: 23 September 2024
Accepted: 13 November 2024
First Online: 27 November 2024
Competing interests
: C.S. reports unconditional honoraria via a Limited company for consultancy and delivery of education from AstraZeneca, Bedfont, Boehringer Inglehieim, Cheisi, GSK, Teva, and Trudell; policy lead PCRS and Co-chair of Early and Accurate Diagnosis working group of Taskforce for Lung Health. D.P. has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; consultancy agreements with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd.) from AstraZeneca, Chiesi, Viatris, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Inside Practice, GlaxoSmithKline, Medscape, Viatris, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme, Teva Pharmaceuticals; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Novartis, Medscape, Teva Pharmaceuticals.; owns 74% of the social enterprise Optimum Patient Care Ltd. (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd. (Singapore); 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. H.P. has received fees for non-promotional talks in sponsored symposia from Teva and Sandoz Pharmaceuticals. The remaining authors declare no competing interests.
